177 related articles for article (PubMed ID: 2149502)
21. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
22. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Yue W; Wang J; Savinov A; Brodie A
Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
Demers LM; Lipton A; Harvey HA; Kambic KB; Grossberg H; Brady C; Santen RJ
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):687-91. PubMed ID: 8476785
[TBL] [Abstract][Full Text] [Related]
24. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat.
Sinha S; Kaseta J; Santner SJ; Demers LM; Bremmer WJ; Santen RJ
Breast Cancer Res Treat; 1998 Mar; 48(1):45-51. PubMed ID: 9541188
[TBL] [Abstract][Full Text] [Related]
25. Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats.
Tominaga T; Yoshida Y; Shimozuma K; Hayashi K; Kosaki G
Eur J Cancer; 1990; 26(5):600-3. PubMed ID: 2144748
[TBL] [Abstract][Full Text] [Related]
26. Blockade of estrogen synthesis with an aromatase inhibitor affects luteal function of the pseudopregnant rat.
Shetty G; Bhatnagar AS; Moudgal NR
J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):347-53. PubMed ID: 8541231
[TBL] [Abstract][Full Text] [Related]
27. The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Lu Q; Yue W; Wang J; Liu Y; Long B; Brodie A
Breast Cancer Res Treat; 1998 Jul; 50(1):63-71. PubMed ID: 9802621
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology of vorozole.
Wouters W; Van Ginckel R; Krekels M; Bowden C; De Coster R
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):617-21. PubMed ID: 8386540
[TBL] [Abstract][Full Text] [Related]
29. Effect of the aromatase inhibitor CGS-16949A on pregnancy and secretion of progesterone, estradiol-17beta, prostaglandins E and F2alpha (PGE; PGF2alpha) and pregnancy specific protein B (PSPB) in 90-day ovariectomized pregnant ewes.
Weems YS; Bridges PJ; LeaMaster BR; Sasser RG; Ching L; Weems CW
Prostaglandins Other Lipid Mediat; 2001 Sep; 66(2):77-88. PubMed ID: 11529553
[TBL] [Abstract][Full Text] [Related]
30. The effect of the aromatase inhibitor, rogletimide (pyridoglutethimide), on guinea pig adrenal cell steroidogenesis and placental microsomal aromatase activity: comparison with aminoglutethimide and CGS 16949A.
Newton CJ; Mehta A; Dowsett M
J Steroid Biochem Mol Biol; 1991 Nov; 39(5A):723-7. PubMed ID: 1659868
[TBL] [Abstract][Full Text] [Related]
31. Effect of estrogen deprivation on the reproductive physiology of male and female primates.
Shetty G; Krishnamurthy H; Krishnamurthy HN; Bhatnagar S; Moudgal RN
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):157-66. PubMed ID: 9365186
[TBL] [Abstract][Full Text] [Related]
32. Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
Tekmal RR; Kirma N; Gill K; Fowler K
Endocr Relat Cancer; 1999 Jun; 6(2):307-14. PubMed ID: 10731124
[TBL] [Abstract][Full Text] [Related]
33. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
34. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC
Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367
[TBL] [Abstract][Full Text] [Related]
35. Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
Houjou T; Wada T; Yasutomi M
Clin Ther; 1993; 15(1):137-47. PubMed ID: 8458043
[TBL] [Abstract][Full Text] [Related]
36. Clinical use of aromatase inhibitors in the treatment of breast cancers.
Manni A
J Cell Biochem Suppl; 1993; 17G():242-6. PubMed ID: 8007705
[TBL] [Abstract][Full Text] [Related]
37. The role of estrogen in the feedback regulation of follicle-stimulating hormone secretion in the female rat.
Bhatnagar AS; Batzl C; Häusler A; Nogués V
J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):161-6. PubMed ID: 8274431
[TBL] [Abstract][Full Text] [Related]
38. A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Tekmal RR; Durgam VR
Cancer Lett; 1997 Sep; 118(1):21-8. PubMed ID: 9310256
[TBL] [Abstract][Full Text] [Related]
39. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.
Browne LJ; Gude C; Rodriguez H; Steele RE; Bhatnager A
J Med Chem; 1991 Feb; 34(2):725-36. PubMed ID: 1825337
[TBL] [Abstract][Full Text] [Related]
40. Effects of the nonsteroidal aromatase inhibitor, Fadrozole, on sexual behavior in male rats.
Bonsall RW; Clancy AN; Michael RP
Horm Behav; 1992 Jun; 26(2):240-54. PubMed ID: 1535332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
